Table 1. Association between IL-1β and clinical features in LUAD and LUSC patients.
| Characteristics | LUAD | LUSC | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients | IL-1β Low (< mediana) | IL-1β High (≥ mediana) | p | All patients | IL-1β Low (< medianb) | IL-1β High (≥ medianb) | p | |
| n | 129 | 64 (49.60%) | 65 (50.40%) | 54 | 27 (50.00%) | 27 (50.00%) | ||
| Age (years) | 0.842 | 0.695 | ||||||
| Median (range) | 65 (48–85) | 65 (49–84) | 65 (48–85) | 64 (50–85) | 64 (50–83) | 64 (51–85) | ||
| Gender | 0.401 | 0.761 | ||||||
| Male | 93 (72.09%) | 44 (34.11%) | 49 (37.98%) | 39 (%72.22) | 20 (37.05%) | 19 (35.17%) | ||
| Female | 36 (27.91%) | 20 (15.50%) | 16 (12.40%) | 15 (27.78%) | 7 (12.97%) | 8 (14.81%) | ||
| Smoke | 0.334 | 0.248 | ||||||
| Yes | 61 (47.29%) | 33 (25.58%) | 28 (21.71%) | 36 (66.67%) | 20 (37.04%) | 16 (29.63%) | ||
| No | 68 (52.71%) | 31 (24.03%) | 37 (28.68%) | 18 (33.33%) | 7 (12.96%) | 11 (20.37%) | ||
| Pathological stagec | 0.330 | 0.023 | ||||||
| IA | 17 (13.18%) | 11 (8.53%) | 6 (4.65%) | 11 (20.37%) | 8 (14.81%) | 3 (5.56%) | ||
| IB | 34 (26.36%) | 20 (15.50%) | 14 (10.85%) | 10 (18.52%) | 8 (14.81%) | 2 (3.71%) | ||
| IIA | 23 (17.83%) | 12 (9.30%) | 11 (8.53%) | 11 (20.37%) | 5 (9.26%) | 6 (11.11%) | ||
| IIB | 32 (24.81%) | 13 (10.08%) | 19 (14.73%) | 13 (24.07%) | 5 (9.26%) | 8 (14.81%) | ||
| IIIA | 11 (8.53%) | 4 (3.10%) | 7 (5.43%) | 8 (14.81%) | 1 (1.85%) | 7 (12.96%) | ||
| IIIB | 12 (9.30%) | 4 (3.10%) | 8 (6.20%) | 1 (1.85%) | 0 (0.00%) | 1 (1.85%) | ||
| Target therapy | 0.537 | NTd | ||||||
| Yes | 65 (50.39%) | 34 (26.36%) | 31 (24.03%) | NTd | NTd | NTd | ||
| No | 64 (49.61%) | 30 (23.26%) | 34 (26.36%) | NTd | NTd | NTd | ||
Mediana = 28.3992 pg/ml Medianb = 43.5495 pg/ml NTd = Not Tested
Pathological stageC was based on NCCN Guidelines Version 3.2011 NSCLC.